HRD-positive/HER2-negative Advanced Breast Cancer
2 clinical trials · Condition
◉ Watch HRD-positive/HER2-negative Advanced Breast Cancer
| Record | Firm | Date |
|---|---|---|
| Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer (NCT06255392) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2024-06-12 |
| Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer (NCT07371910) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2024-06-12 |
Track HRD-positive/HER2-negative Advanced Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.